Emergence of drug resistance to first line ART has been well documented and after a decade or so of ART roll out in resource poor settings we are now beginning to see drug resistance to second line drugs. What exactly do these protease inhibitor genotype mutations mean for the resource poor settings?
Dear Ivan,
This is a great resource for drug resistance, and mutations. http://hivdb.stanford.edu/. Also Darunavir/Ritonavir if available it may be an option.
Dear Ivan,
These mutations, if all appear together in a patient, causing broad cross-resistance to all PI except for DRV.
They are usually induced by IDV or LPV/r and are usually seen in patients who have received multiple treatments with PI
I47V and V82S often also affect the TPV
Thank You Martin. the reality is there is no provision for Integrase inhibitors available on the national treatment guidelines. the Gov't uses the principle of mass treatment for the majority, with a public health approach but nothing is in place to deal with individual cases of emerging failure.
- Badges
- Science topic
- Similar topics
- Psychology